Princess Margaret Cancer Centre Trials Blood Test to Detect Cancer Recurrence Early

Researchers are testing whether a liquid biopsy blood test can catch lingering cancer cells after treatment, potentially triggering preventive therapies.

A blood test that can detect microscopic traces of cancer left behind after treatment is now the subject of a clinical trial at Princess Margaret Cancer Centre. The approach, known as a liquid biopsy, is designed to identify tiny amounts of remaining cancer that standard imaging or examination might miss. The trial is investigating whether a positive result on this test — indicating residual cancer — could be used to direct patients toward additional experimental treatments aimed at preventing a full recurrence before it takes hold. Liquid biopsies work by scanning the bloodstream for fragments of cancer-related DNA or cells shed by tumors. The concept has gained traction in oncology research as a potentially less invasive way to monitor cancer status compared to surgical biopsies or imaging scans.

Why it matters

Detecting residual cancer earlier could allow doctors to intervene before a relapse becomes detectable through conventional means, potentially improving survival outcomes for patients who appear cancer-free after initial treatment.

What's next

Results from the Princess Margaret Cancer Centre trial will determine whether liquid biopsy results can reliably guide decisions about additional post-treatment therapies.

Key facts

• The trial is being conducted at Princess Margaret Cancer Centre
• The blood test being studied is a liquid biopsy
• The test aims to detect small amounts of cancer remaining after treatment
• Patients with a positive test result could be eligible for additional experimental treatments
• The goal of those follow-on treatments would be to prevent cancer from returning

Bias & framing notes

Both sources are from the same outlet, globalnews.ca, and appear to cover the same story with slightly different headline framing — one emphasizes the research being 'underway,' the other that 'researchers are on it.' No independent second outlet is present, and neither article provides granular trial details such as sample size, cancer type, or timeline, limiting the depth of verification possible.